

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Atty. Docket No. 1765.80234

Page 1

Assistant Commissioner of Patents
Box Patent Applications
Washington, D.C. 20231

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): Michael L. Vazquez

Title of Invention: α and β -Amino Acid Hydroxyethylamino Sulfonamides Useful As Retroviral Protease Inhibitors

- ☒ Continuation
☐ Divisional
☐ Continuation-in-Part

of prior application No. 08/294,468, filed August 23, 1994

1. ☒ Specification 274 pages (including specification, claims, abstract) / 20 claims (2 independent)
2. ☒ Declaration/Power of Attorney:
 - ☒ Copy from Prior Application (for continuation or divisional application)
 - ☐ Newly Executed Declaration (for CIP application)
 - ☐ Deferred under 37 C.F.R. § 1.53(f)
 - ☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)
 - ☒ Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
3. ☒ This Application has no drawings.
4. ☒ Preliminary Amendment
5. ☐ Information Disclosure Statement
 - ☐ Form 1449
 - ☐ A copy of each cited prior art reference
6. ☒ Assignment
 - ☐ Assignment with Cover Sheet attached
 - ☒ Assignment filed in prior application. Application assigned to: **G.D. Searle & Co.**

JC518 U.S. PTO
09/288080
04/08/99

A

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Page 2

Atty. Docket No. 1765.80234

7. ☐ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)

8. ☐ Priority document(s)

9. ☐ Small Entity Statement

- ☐ Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
☐ is attached
☐ is no longer claimed

10. ☐ Microfiche Computer Program (Appendix)

11. ☐ Nucleotide and/or Amino Acid Sequence Submission

- ☐ Computer Readable Copy
☐ Paper Copy (identical to computer copy)
☐ Statement verifying identity of above copies

12. Calculation of Fees (upon entry of Preliminary Amendment):

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			
			\$760.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	0	18.00	\$0.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	0	78.00	\$0.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	260.00	\$0.00
Subtotal - Filing Fee Due			\$760.00
MULTIPLY BY			
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		\$0.00
TOTAL FILING FEE DUE			\$760.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
GRAND TOTAL DUE			\$760.00

13. PAYMENT is:

- ☒ included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18
☐ not included, but deferred under 37 C.F.R. § 1.53(f).

A

1. The first step is to identify the problem or question that needs to be addressed. This involves understanding the context and the specific requirements of the task.

Atty. Docket No. 1765.80234

- Banner & Witcoff, Ltd.**
1001 G Street, N.W.
Washington, D. C. 20001-4597
Telephone: (202) 508-9100
Facsimile: (202) 508-9299

15. Other: _____

Date: April 8, 1999

By: Joseph M. Skerpon
Joseph M. Skerpon
Reg. No. 29,864

JMS/rkb

A